Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 52.31% | 49.25% | 51.06% | 54.48% | -72.86% |
| Total Depreciation and Amortization | 116.93% | 328.03% | 725.86% | 1,253.57% | 807.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -167.97% | -155.51% | -161.21% | -166.98% | 1,332.04% |
| Change in Net Operating Assets | 562.12% | 970.24% | 25.54% | 67.23% | -119.06% |
| Cash from Operations | -10.38% | 1.63% | -13.61% | 1.83% | -17.64% |
| Capital Expenditure | 100.00% | 100.00% | 93.39% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 105.79% | 100.00% | 93.39% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.78% | -91.05% | -85.81% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -- | -- | -- |
| Cash from Financing | -100.07% | -91.36% | -87.59% | -- | 12,377.81% |
| Foreign Exchange rate Adjustments | -184.22% | 2,469.40% | -138.58% | 339.30% | 310.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -332.47% | -410.06% | -354.92% | 147.97% | 155.88% |